Freeport-McMoRan vs Southern Copper
FCX and SCCO side by side, both in materials. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FCX and SCCO compare
Southern Copper is the larger company, worth 1.7 times as much as Freeport-McMoRan ($148B against $89.7B).
On earnings, Southern Copper is cheaper: it trades at 23.1× trailing earnings, against 30.8× for Freeport-McMoRan.
Southern Copper grew revenue faster over the last twelve months (38.7% versus 0.19% for Freeport-McMoRan).
Both pay dividends: Freeport-McMoRan yields 0.96% and Southern Copper 2.2%.
Southern Copper scores higher on the StockData Score (11 against 5 for Freeport-McMoRan), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FCX | SCCO |
|---|---|---|
| Size and price | ||
| Market cap | $89.7B | $148B |
| Share price | $62.47 | $177.53 |
| Change, 1 year | 48.1% | 25.3% |
| Change, 5 years | 68.7% | 199% |
| Beta (5Y) | 1.45 | 1.09 |
| Employees | 29K | 17K |
| StockData Score | ||
| Total score | 5 | 11 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 4 (better) |
| Performance score | 1 | 1 |
| Health score | 3 | 4 (better) |
| Dividend score | 1 | 2 (better) |
| Valuation | ||
| P/E | 30.8× | 23.1× (better) |
| P/S | 3.5× (better) | 8.7× |
| P/B | 4.5× (better) | 11.0× |
| EV/EBITDA | 11.8× (better) | 13.5× |
| P/FCF | – | 26.5× |
| PEG | – | 1.50 |
| FCF yield | – | 3.8% |
| Fair value | $48.63 | $153.82 |
| Margin of safety | −28.5% | −15.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 0.19% | 38.7% (better) |
| Revenue growth, 5Y average | 12.8% (better) | 10.9% |
| EPS growth (TTM) | 53.8% | 67.0% (better) |
| EPS growth, 5Y average | – | 20.9% |
| Profitability | ||
| Gross margin | 27.1% | 65.2% (better) |
| Operating margin | 26.8% | 58.6% (better) |
| FCF margin | – | 32.7% |
| Return on invested capital | 19.9% | 49.0% (better) |
| Financial health | ||
| Debt / equity | 0.47 (better) | 0.59 |
| Net debt / EBITDA | 0.59 (better) | −0.01 |
| Current ratio | 2.07 | 4.31 (better) |
| Altman Z-score | 2.99 | 9.99 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.96% | 2.2% (better) |
| Years of dividend growth | 0 | 1 (better) |
| Dividend growth, 5Y average | – | 15.6% |
| Buyback yield | 0.23% | – |
| Shareholder yield | 1.2% | 2.2% (better) |
| Ownership | ||
| Held by institutions | 86.9% | 9.2% |
| Held by insiders | 0.60% | 0.07% |
| Insider net buying, 12 months | −$46.0M | −$3.4M (better) |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 1.8% | 1.3% |
Go deeper
- FCX stock overview
- FCX income statement
- FCX valuation and score
- SCCO stock overview
- SCCO income statement
- SCCO valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.